Skip to main content
. 2022 Sep 13;323(5):G428–G438. doi: 10.1152/ajpgi.00100.2022

Table 2.

Linear mixed model results for IL-6, IL-8, and MCP-1 using Control subjects as baseline

IL-6
IL-8
MCP-1
Coefficient Estimates P Estimates P Estimates P
 (Intercept) −1.57
(−2.56–−0.57)
0.002 1.14
(0.46–1.82)
0.001 5.13
(4.67–5.59)
<0.001
 Age 0.01
(0.00–0.02)
0.032 0.01
(0.00–0.01)
0.025 0.00
(−0.00–0.01)
0.149
 Male 0.43
(0.06–0.79)
0.023 0.15
(−0.09–0.39)
0.219 0.09
(−0.08–0.26)
0.299
 Body mass index 0.01
(−0.02–0.03)
0.518 0.01
(−0.01–0.03)
0.249 0.01
(−0.00–0.02)
0.226
 Time from pain onset (days) 0.01
(−0.15–0.16)
0.947 0.00
(−0.14–0.14)
0.980 −0.04
(−0.12–0.03)
0.275
AP severity
 MAP 2.01
(1.33–2.69)
<0.001 1.17
(0.65–1.69)
<0.001 0.64
(0.32–0.96)
<0.001
 MSAP 3.82
(3.00–4.64)
<0.001 1.22
(0.58–1.86)
<0.001 0.61
(0.22–1.00)
0.002
 SAP 6.28
(5.45–7.10)
<0.001 3.56
(2.93–4.20)
<0.001 1.85
(1.45–2.24)
<0.001
Time by AP severity interaction
 MAP 0.01
(−0.19–0.20)
0.940 −0.05
(−0.23–0.12)
0.570 −0.13
(−0.23–−0.03)
0.008
 MSAP −0.18
(−0.39–0.04)
0.112 0.00
(−0.19–0.20)
0.969 −0.03
(−0.14–0.08)
0.641
 SAP −0.30
(−0.50–−0.09)
0.005 −0.28
(−0.47–−0.10)
0.003 −0.08
(−0.18–0.03)
0.147
Random effects
 σ2 0.52 0.43 0.13
 τ00 1.09 Person.ID 0.38 Person.ID 0.21 Person.ID
 ICC 0.68 0.47 0.62
 N 165 Person.ID 165 Person.ID 165 Person.ID
 Observations 439 439 438
Marginal R2 /Conditional R2 0.689/0.900 0.527/0.748 0.514/0.815

All cytokine concentrations were transformed on a log scale before mixed model estimation. All models use the control series as baseline. A significant result in AP severity denotes a log scale shift from baseline control levels for that category. A significant result in Time by AP Severity denotes a significant change (±) in slope from the baseline control slope. Significance P values with P < 0.05 are in bold for emphasis. IL-8, interleukin-8; IL-6, interleukin-6; MCP-1, monocyte chemoattractant protein-1; MAP, mild acute pancreatitis; MSAP, moderately severe acute pancreatitis; SAP, severe acute pancreatitis.